Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
hemic and lymphatic diseases | D006425 |
immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
JAYPIRCA | Loxo Oncology | N-216059 RX | 2023-01-27 | 2 products, RLD, RS |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
mantle-cell lymphoma | — | D020522 | C83.1 |
Expiration | Code | ||
---|---|---|---|
PIRTOBRUTINIB, JAYPIRCA, LOXO ONCOL | |||
2030-01-27 | ODE-424 | ||
2028-01-27 | NCE |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | 4 | 4 | — | 1 | 10 |
Mantle-cell lymphoma | D020522 | — | C83.1 | 2 | 3 | 1 | — | 1 | 6 |
Lymphoid leukemia | D007945 | — | C91 | — | 1 | 1 | — | — | 2 |
B-cell leukemia | D015448 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Waldenstrom macroglobulinemia | D008258 | — | C88.0 | 2 | 2 | — | — | 1 | 4 |
B-cell lymphoma | D016393 | — | — | 2 | 2 | — | — | — | 3 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 2 | — | — | — | 3 |
B-cell lymphoma marginal zone | D018442 | — | C88.4 | 1 | 1 | — | — | — | 2 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 1 | — | — | — | 1 |
Leukemia | D007938 | — | C95 | — | 1 | — | — | — | 1 |
Hematologic neoplasms | D019337 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
Drug common name | PIRTOBRUTINIB |
INN | pirtobrutinib |
Description | Pirtobrutinib, sold under the brand name Jaypirca, is an anticancer medication that is used to treat mantle cell lymphoma. It inhibits B cell lymphocyte proliferation and survival by binding and inhibiting Bruton's tyrosine kinase (BTK). It is taken by mouth.
|
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors Bruton's (Btk) inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn([C@@H](C)C(F)(F)F)c(N)c2C(N)=O)cc1 |
PDB | 8FLN |
CAS-ID | 2101700-15-4 |
RxCUI | — |
ChEMBL ID | CHEMBL4650485 |
ChEBI ID | — |
PubChem CID | 129269915 |
DrugBank | DB17472 |
UNII ID | JNA39I7ZVB (ChemIDplus, GSRS) |